TXMD TherapeuticsMD
- 1.890
- +0.030+1.61%
- 1.900
- +0.010+0.53%
TherapeuticsMD News
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
Press Release: TherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD Announces Full Year 2023 Financial Results -- Evaluation of strategic alternatives continues BOCA RATON, Fla.--(BUSINESS WIRE)--March 29, 2024-- TherapeuticsMD, Inc. ("TherapeuticsMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD
25 Countries With Highest Abortion Rates
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock?A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indic
TherapeuticsMD(TXMD.US) Officer Sells US$43,683.9 in Common Stocks
$TherapeuticsMD(TXMD.US)$ Officer Walker Marlan D sold 19,050 shares of Common Stocks on Dec 6, 7, 2023 at an average price of $2.2931 for a total value of $43,683.9.Source: Announcement What is state
Stocks to Watch: Getty Images, TherapeuticsMD, Solid Biosciences
By Denny Jacob Getty Images Holdings lowered its 2023 outlook, citing challenges ranging from strikes in Hollywood to a stronger dollar. Shares retreat 5.8% in after-market trading. TherapeuticsMD,
TherapeuticsMD Exploring Strategic Alternatives for Company
TherapeuticsMD Q3 EPS $(0.13) Misses $(0.05) Estimate
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 95.27 percent increase over losses of $(2.7
Therapeutics MD GAAP EPS of -$0.13
TherapeuticsMD: Evaluating Strategic Alternatives That May Include an Acquisition, Merger, Other Business Combination, Sale of Assets, or Other Strategic Transactions >TXMD
TherapeuticsMD: Evaluating Strategic Alternatives That May Include an Acquisition, Merger, Other Business Combination, Sale of Assets, or Other Strategic Transactions >TXMD
TherapeuticsMD: Hasn't Set Timetable for Completion of Exploration Process and Doesn't Intend to Disclose Further Developments Unless and Until It Is Determined That Disclosure Is Appropriate or Necessary >TXMD
TherapeuticsMD: Hasn't Set Timetable for Completion of Exploration Process and Doesn't Intend to Disclose Further Developments Unless and Until It Is Determined That Disclosure Is Appropriate or Neces
TherapeuticsMD 3Q Loss/Shr 13c >TXMD
TherapeuticsMD 3Q Loss/Shr 13c >TXMD
TherapeuticsMD Announces Third Quarter 2023 Financial Results
Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company
Cantor Fitzgerald Reiterates Neutral on TherapeuticsMD, Maintains $5 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates TherapeuticsMD (NASDAQ:TXMD) with a Neutral and maintains $5 price target.
TherapeuticsMD Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 08/17/2023 39.66% Cantor Fitzgerald → $5 Reiterates Neutral → Neutral 01/11/2023 39.66% Cantor Fitzgerald
TherapeuticsMD Q2 EPS $(0.24) Misses $(0.07) Estimate, Sales From Cont Ops $400.00K Miss $500.00K Estimate
TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.07) by 242.86 percent. This is a 93.02 percent increase over losses of $(
Therapeutics MD GAAP EPS of -$0.24
Press Release: TherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD Announces Second Quarter 2023 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)--August 14, 2023-- TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company
TherapeuticsMD 2Q Cont Ops Loss/Shr 24c >TXMD
TherapeuticsMD 2Q Cont Ops Loss/Shr 24c >TXMD
Analysis
Price Target
No Data
